KRT14 and neoplasm: Notably, we confirmed sustained MAPK activation in both models (Fig. 1d) and onset of tumour formation with a tumour-free survival rate of 22 days for the K14:HRASG12V/+ model and 58 days for the Ivl:HRASG12V/+ model (Fig. 1b, c and Supplementary Fig. 1b).